---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335101"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2026-08-05T20:10:16+00:00"
generated_at: "2026-08-05T20:11:34.421916+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics Q2 net loss $32.5M; positive Phase 1 data for ELVN-001 in CML; cash $895M into 2030

## Summary
- Net loss of $32.5M for Q2 2026 vs $25.3M in Q2 2025; R&D expenses $29.0M.
- Cash, cash equivalents and marketable securities of $895.2M as of June 30, 2026, expected to fund operations into 2030.
- ELVN-001 Phase 1 data: 61% overall MMR, 48% MMR by 24 weeks in 80mg QD cohort; favorable safety profile.
- FDA alignment on Phase 3 ENABLE-2 trial design; 80mg QD selected as recommended dose; Fast Track Designation granted.
- Expect to initiate ENABLE-2 Phase 3 trial in H2 2026.

## SEC filing metadata
- accession: 0001193125-26-335101
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2026-08-05T20:10:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/0001193125-26-335101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/elvn-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335101
- JSON: https://secwatch.observer/filing/0001193125-26-335101.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.